Today’s asthma diagnosis is slow, expensive, and often inaccurate. Patients wait weeks for results. Devices are bulky, require lab setups, or deliver inconsistent readings.
Existing solutions like FeNO, NIOX, and Owlstone require complex equipment, trained operators, and significant time making them impractical for everyday clinical use or home monitoring.
We built Exhale-Dx® to change all of that because current solutions are failing patients.
Four simple steps. Results in under 60 seconds.
The patient exhales into the Exhale-Dx™ device. No needles, no blood, no lab required. Completely non-invasive.
The device captures breath biomarkers across 13 distinct parameters from the exhaled sample in real time.
Our deep learning AI framework processes the breath data, detecting asthma patterns and calculating attack probability.
Results delivered in under 1 minute. Clinicians and patients receive actionable insights before an attack occurs.
Proven in published clinical trials across adults and children
Diagnostic Accuracy
Advance Attack Prediction
Reduction in Asthma Attacks
Breath Parameters Analysed
Our proprietary deep learning framework sits at the heart of Exhale-Dx®. Trained on clinical breath data from patients across multiple sites, it identifies subtle biomarker patterns invisible to the human eye.
The framework analyses 13 breath parameters simultaneously including amplitude, variability, and chemical composition to build a complete picture of a patient’s respiratory health.
This technology is protected by two accepted international patent applications.
Exhale-Dx® uniquely combines speed, ease, and remote monitoring where competitors fall short
| Feature | Exhale-Dx® | FeNO / NIOX | Owlstone | Breathomix |
|---|---|---|---|---|
| Results in under 1 minute | ✓ | ✕ | ✕ | ✕ |
| Non-invasive | ✓ | ✕ | ✕ | ✕ |
| No lab setup required | ✓ | ✓ | ✓ | ✓ |
| Remote monitoring ready | ✓ | ✕ | ✕ | ✕ |
| AI-powered attack prediction | ✓ | ✕ | ✕ | ✕ |
| Home use compatible | ✓ | ✕ | ✕ | ✕ |
| Internationally patented | ✓ | ✕ | ✕ | ✕ |
Exhale-Dx® is protected by two accepted international patent applications covering the 13 breath parameters and the deep learning framework at its core. Our intellectual property ensures Breath Predict maintains a strong competitive position as we scale commercially across the UK, EU, and USA.
Exhale-Dx® has been evaluated in clinical feasibility studies across adults and children, with further Oxford-based, NIHR-backed research currently underway.
Designed for real-world deployment, Exhale-Dx® fits GP clinics, hospital pathways and home monitoring, and supports pharmaceutical partners with objective respiratory endpoints.
Breath Predict is progressing Exhale-Dx through recognised regulatory pathways in the UK, Europe and the United States.
UK regulatory pathway for in-vitro diagnostic and medical device conformity.
European regulatory pathway under the In Vitro Diagnostic Regulation framework.
US regulatory pathway for diagnostic device submission and review.
Like Nothing You’ve Seen. Contact Us Today & Experience New Diagnostic Solutions.
